28 August 2019 - Neurolixis CSO to present novel antidepressants at Copenhagen ECNP Meeting

Adrian Newman-Tancredi, PhD, DSc, will present on novel antidepressant drugs at the forthcoming European College of Neuropsychopharmacology (ECNP) Congress to be held on 7-10 September in Copenhagen, Denmark. Together with Prof. Luc Zimmer of the Cermep Brain Imaging center (Lyon, France), Dr. Newman-Tancredi will lead a 'Brainstorming Session' on rapid-acting antidepressant drugs (RAADs) such as ketamine. Drug discovery efforts at Neurolixis have identified novel 'biased agonists', e.g. NLX-101, that show striking antidepressant activity in animal models. Moreover, the session will discuss how brain imaging technologies, including PET, fMRI and fUS, can help investigate brain region-specific effects of novel antidepressants.

Brainstorming session BS.02
Title: "The search for safe and rapid-acting antidepressants in the post-ketamine era: challenges for biased agonists"
Date: Sunday 9 September at 7h45 am, Room B2.
Chair: Kamilla Miskowiak, Professor of Cognitive Neuropsychiatry at the University of Copenhagen.

For full details of the session see the meeting website.


20 August 2019 - First human brain imaging of serotonin 5-HT1A receptors using 18F-NLX-112 as agonist PET tracer

The Neurolixis lead compound, NLX-112, is at the heart of a new brain imaging investigation of functionally-active serotonin 5-HT1A receptors in humans. NLX-112, also known as befiradol or F13640, was radiolabeled and administered to healthy adults as part of an ongoing clinical study led by Prof. Luc Zimmer of the Cermep brain imaging center in Lyon, France.

The study shows that, unlike previous radiotracers, 18F-labeled NLX-112 binds to 5-HT1A receptors which are functionally-responsive, and shows accentuated labeling in specific cortical brain regions. The first data from the study were published as the 'Image of the month' in the 'European Journal of Nuclear Medicine and Molecular Imaging'. 

18F-F13640 PET imaging of functional receptors in humans
Colom M., Costes N., Redouté J., Dailler F., Gobert F., Le bars D., Billard T., Newman-Tancredi A., Zimmer L. 
Eur J Nucl Med Mol Imaging (2019).

Full Press Release Here.